{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '7.1.1.', 'Patient Education Module', 'Patients will be educated by Investigators or trained healthcare professionals on coagulation and', 'general considerations with regard to managing hemophilia in the clinical setting of lowered-AT.', 'This will be performed as specified in the Schedule of Assessments (Table 1).', '7.1.2.', 'Inhibitor Status', 'Patients inhibitor status will be determined as specified in the Schedule of Assessments (Table 1)', 'by Nijmegen modified Bethesda assay.', '7.1.3.', 'FibroScan or FibroTest/APRI', 'A FibroScan or FibroTest/APRI will be performed according to the Schedule of Assessments', '(Table 1) to rule out cirrhosis in patients with a history of Hepatitis C.', '7.2.', 'Efficacy Assessments', 'Bleeding Episode Definitions', 'A bleeding episode is defined as any occurrence of hemorrhage that requires administration of', 'factor concentrates or BPA infusion, eg, hemarthrosis, muscle, or mucosal bleeding. Since', 'bleeding episodes are recorded as an efficacy assessment of fitusiran, these will not be treated as', 'AEs unless they meet any of the SAE criteria listed in Section 7.5.6.1.', 'The definition of bleeding episode types described below is based on consensus opinion of', 'International Society on Thrombosis and Haemostasis (ISTH) as reflected in a recent', 'publication.[12', 'The start time of a bleeding episode will be considered the time at which symptoms of a bleeding', 'episode first develop. Bleeding or any symptoms of bleeding at the same location that occurs', 'within 72 hours of the last injection used to treat a bleeding episode at that location will be', 'considered a part of the original bleeding event, and will count as one bleeding episode towards', 'the ABR. Any bleeding symptoms that begin more than 72 hours from the last injection used to', 'treat a bleeding episode at that location will constitute a new bleeding event.', 'A spontaneous bleeding episode is a bleeding event that occurs for no apparent or known reason,', 'particularly into the joints, muscles, and soft tissues.', 'A joint bleeding episode is characterized by an unusual sensation in the joint (\"aura\") in', 'combination with 1) increasing swelling or warmth over the skin over the joint, 2) increasing', 'pain, or 3) progressive loss of range of motion or difficulty in using the limb as compared with', 'baseline.', 'A muscle bleed may be characterized by pain, swelling and loss of movement over the affected', 'muscle group.', 'A target joint is defined as a joint where 3 or more spontaneous bleeding episodes in a single', 'joint within a consecutive 6-month period has occurred; where there have been 2 bleeding', 'episodes in the joint within a consecutive 12-month period the joint is no longer considered a', 'target joint.', 'Property of the Sanofi Group - strictly confidential', '53']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'A traumatic bleeding episode is one that is caused by a known injury or trauma. Bleeding', 'episodes sustained during sports and recreation will be counted as traumatic bleeding episodes,', 'but patients will be asked to indicate in the eDiary that the event occurred during such activities.', 'Training will be provided on this and other aspects of eDiary use (see Section 7.2.1).', 'Annualized bleeding rate will be calculated as described in Section 8.2.5.1. Bleeding episodes', 'will be managed according to Section 6.3.1.', '7.2.1.', 'Electronic Diary', 'Patients will be issued an eDiary to record all bleeding events and all doses of BPAs', 'administered during the conduct of the study. Entries are to be made in a timely manner, and it', 'is preferred that doses are entered immediately upon administration or within 24 hours. Patients', 'will be prompted to enter bleeding location, severity, causality (spontaneous or traumatic), doses', 'of bypass agents, and reasons for dosing (prophylaxis, treatment of a bleed, and preventive dose', 'for anticipated activity). Training of patients should be documented in the appropriate source', 'record.', 'The Sponsor or an independent delegate will review diary entries for data quality to identify', 'issues such as subjects who may need retraining on diary use and timely entry of bleeding', 'episode information.', 'Bleeding episodes will be recorded by the patient in the eDiary, and reviewed by the Investigator', '(and Sponsor or independent delegate) continuously for the study duration. The site will contact', 'the patient at a minimum interval of every 2 weeks per schedule of assessments to review diary', 'records and ensure that the patient is utilizing the device appropriately.', 'Sites will be notified when patients enter initial treatments for bleeding events into their eDiaries.', 'If the dose amount exceeds the recommended dose according to the bleeding episode', 'management plan, the patient must be contacted as soon as possible, preferably within 24-48', \"hours of receiving the alert. At the time of contact the patient's clinical condition will be\", 'reviewed along with the dose and efficacy of the treatment given, and the Investigator will', 'provide appropriate guidance regarding further management of the bleeding episode. The site', 'will also receive an alert, and must make contact with the patient as soon as possible if a third', 'dose of product is administered for a single bleed, to review clinical condition, the need for', 'further therapy, and appropriate ongoing management of the bleeding episode required to', 'achieve hemostasis.', 'In addition, patients will be instructed to contact the site if they feel they need to administer BPA', 'at a higher dose level or higher frequency than their bleeding episode management plan', 'recommends, or if more than two doses are required to achieve hemostasis.', 'Complete instructions will be provided in the Study Manual.', '7.3.', 'Pharmacodynamic Assessments', 'In this study, AT activity level and thrombin generation will be collected as measurements of PD', 'effect. These measurements will be collected and analyzed centrally for research purposes. As', 'interpretation is uncertain, thrombin generation results will not be used to adjust dosing of', 'fitusiran or guide other elements of study conduct or clinical management and will not be shared', 'Property of the Sanofi Group - strictly confidential', '54']\n\n###\n\n", "completion": "END"}